Skip to main content

Advertisement

SpringerLink
Log in

IgA vasculitis during secukinumab therapy

  • Case Based Review
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Psoriatic arthritis is a chronic, seronegative spondyloarthropathy associated with psoriasis, depending on patient presentation treatment options range from non-pharmacologic measures to NSAIDs, DMARDs, and biologics. Secukinumab is a human monoclonal antibody that specifically targets interleukin-17 and has been shown to be highly effective in the treatment of psoriatic arthritis. As the use of IL-17 inhibitors has been approved in the treatment of psoriatic arthritis, clinicians need to be aware of unusual adverse events not previously observed in clinical trials. We report a rare case of Henoch-Schönlein purpura vasculitis induced by secukinumab in a 39-year-old patient. Therefore, using biologic drugs in clinical practice should be aware that cutaneous vasculitis may be triggered by anti-IL17 treatment, and early diagnosis always helps to decrease morbidity and reduce the amount of time to recovery as well as the impact on the quality of life disruption.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Frieder J, Kivelevitch D, Menter A (2018) Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis. Ther Adv Chronic Dis 9(1):5–21. https://doi.org/10.1177/2040622317738910

    Article  CAS  PubMed  Google Scholar 

  2. Koenders MI, van den Berg WB (2016) Secukinumab for rheumatology: development and its potential place in therapy. Drug Des Devel Ther 10:2069–2080. https://doi.org/10.2147/DDDT.S105263

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Ritchlin CT, Colbert RA, Gladman DD (2017) Psoriatic arthritis. N Engl J Med 376:957–970. https://doi.org/10.1056/NEJMra1505557

    Article  PubMed  Google Scholar 

  4. Armstrong AW, Papp K, Kircik L. Secukinumab (2016) Review of clinical evidence from the pivotal studies ERASURE, FIXTURE, and CLEAR. J Clin Aesthet Dermatol9(6 Suppl 1):S7-S12

  5. Armstrong AW, Vender R, Kircik L (2016) Secukinumab in the treatment of palmoplantar, nail, scalp, and pustular psoriasis. J Clin Aesthet Dermatol 9(6 Suppl 1):S12–S16

    PubMed  PubMed Central  Google Scholar 

  6. Villani A, De Fata SG, Nappa P, Megna M, Fabbrocini G, Napolitano M (2019) Cutaneous leucocytoclastic vasculitis during secukinumab treatment. G Ital Dermatol Venereol. https://doi.org/10.23736/S0392-0488.18.06203-X

  7. Sokumbi O, Wetter DA, Makol A, Warrington KJ (2012) Vasculitis associated with tumor necrosis factor alpha inhibitors. Mayo Clin Proc 87:739–745. https://doi.org/10.1016/j.mayocp.2012.04.011

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Saint Marcoux B, De Bandt M, CRI (Club Rhumatismes et Inflammation) (2006) Vasculitides induced by TNFα antagonists: a study in 39 patients in France. Joint Bone Spine 73(6):710–713. https://doi.org/10.1016/j.jbspin.2006.02.010

    Article  CAS  PubMed  Google Scholar 

  9. Jue X, Yan L, Lei W, Guoxiang R et al (2015) Expansion of circulating T follicular helper cells in children with acute Henoch-Schönlein purpura, Hindawi Publishing Corporation. J Immunol Res 742535:1–9. https://doi.org/10.1155/2015/742535

    Article  CAS  Google Scholar 

  10. Veale DJ, Fearon U (2018) The pathogenesis of psoriatic arthritis. Lancet 391(10136):2273–2284

    Article  CAS  Google Scholar 

  11. Dumoutier L, Van Roost E, Ameye G, Michaux L, Renauld JC (2000) IL-TIF/IL-22: genomic organization and mapping of the human and mouse genes. Genes Immun 1(8):488–494. https://doi.org/10.1038/sj.gene.6363716

    Article  CAS  PubMed  Google Scholar 

  12. Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA et al (2000) Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408(6808):57–63. https://doi.org/10.1038/35040504

    Article  CAS  PubMed  Google Scholar 

  13. Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T et al (2007) IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 8(9):967–974. https://doi.org/10.1038/ni1488

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank the patient described for allowing us to share his details and provided informed consent.

Funding

The study did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

  1. Clinic for Internal Medicine, University Hospital Split, Spinciceva 1, 21 000, Split, Croatia

    Dijana Perkovic & Petra Simac

  2. Clinic for Heart and Cardiovascular Diseases, University Hospital Split, Spinciceva 1, 21 000, Split, Croatia

    Josip Katic

Authors
  1. Dijana Perkovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Petra Simac
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Josip Katic
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

The work presented here was carried out in collaboration between all authors. Dijana Perkovic, Petra Simac, and Josip Katic defined the research theme. Petra Simac and Josip Katic performed the literature review and wrote the paper. Dijana Perkovic has been involved in drafting the manuscript or revising it critically for important intellectual content and has given final approval of the version to be published. All authors have contributed to, seen, and approved the manuscript.

Corresponding author

Correspondence to Josip Katic.

Ethics declarations

Disclosures

None.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Perkovic, D., Simac, P. & Katic, J. IgA vasculitis during secukinumab therapy. Clin Rheumatol 40, 2071–2073 (2021). https://doi.org/10.1007/s10067-020-05364-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-020-05364-1

Keywords

Search

Navigation